DARE Stock Analysis: Buy, Sell, or Hold?
DARE - Dare Bioscience, Inc. Common Stock
$0.81
-0.01 (-0.96%)
▼
5d:
+0.22%
30d:
-36.56%
90d:
-65.74%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When DARE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: DARE shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: DARE shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: DARE is currently trading at $0.81, which is considered oversold relative to its 30-day fair value range of $1.01 to $1.72. From a valuation perspective, the stock is trading at a discount (Forward PE: -2.0) compared to its historical average (3.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DARE is in a downtrend. Immediate support is located at $0.75, while resistance sits at $1.61.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.33 (+916.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DARE is in a downtrend. Immediate support is located at $0.75, while resistance sits at $1.61.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.33 (+916.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.01 -
$1.72
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 916.4% below Wall St target ($8.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.01 -
$1.72
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.75
Resistance Level
$1.61
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.98
Wall Street Target
$8.33
(+916.4%)
Revenue Growth (YoY)
499.6%
PE vs Historical
-2.0 vs 3.6
CHEAP
Share & Embed Analysis
Last updated: August 24, 2026 10:46 AM ET
Data refreshes hourly during market hours. Next update: 11:46 AM
Data refreshes hourly during market hours. Next update: 11:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DARE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 40 SELL |
